<DOC>
	<DOCNO>NCT02503293</DOCNO>
	<brief_summary>A randomised , cross-over study compare quality life satisfaction primary immunodeficient patient treat subcutaneous injection Gammanorm® 165 mg/mL administer two different delivery device : injection use pump rapid push .</brief_summary>
	<brief_title>A Study Compare Quality Life Satisfaction Primary Immunodeficient Patients Treated With Subcutaneous Injections Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices : Injections Using Pump Rapid Push</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>Inclusion criterion : Adult patient ( ≥ 18 year ) . Presenting primary immunodeficiency . Having receive subcutaneous injection immunoglobulin home use automatic pump syringe least 1 month time inclusion . For investigator decides maintain immunoglobulin replacement therapy subcutaneous injection Gammanorm® 165 mg/mL home . Freely give write informed consent patient . Women childbearing potential must negative result pregnancy test ( human chorionic gonadotropine [ HCG ] base assay ) need practice contraception use method proven reliability duration study . • Participating another interventional clinical study receive investigational medicinal product within three month study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>